Cellular processes

• The Implications of Cannabinoid-Induced Metabolic Dysregulation for Cellular Differentiation and Growth (02 Sep 2024)
  
• Perturbation of 3D nuclear architecture, epigenomic dysregulation and aging, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 1–aging and epigenomics (02 Sep 2024)
  
• Perturbation of 3D nuclear architecture, epigenomic aging and dysregulation, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 2—Metabolome, immunome, synaptome (02 Sep 2024)
  
• Cannabinoid receptors type 2: Function and development in agonist discovery from synthetic and natural sources with applications for the therapy of osteoporosis (02 Sep 2024)
  
• Molecular Insights into Epigenetics and Cannabinoid Receptors (27 Aug 2024)
  
• Therapeutic Potential of β-Caryophyllene: A Dietary Cannabinoid in Diabetes and Associated Complications (20 Aug 2024)
  
• Inflammation and cancer: friend or foe? (24 May 2024)
  
• The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells (05 Sep 2022)
  
• Cannabidiol Induces Cell Death in Human Lung Cancer Cells and Cancer Stem Cells (05 Sep 2022)
  
• The strengths and limits of cannabinoids and their receptors in cancer: Insights into the role of tumorigenesis-underlying mechanisms and therapeutic aspects (27 Aug 2022)
  
• 1,2,3-Triazole derivatives as highly selective cannabinoid receptor type 2 (CB2) agonists (27 Aug 2022)
  
• Cannabinoids, their cellular receptors, and effects on the invasive phenotype of carcinoma and metastasis (05 Aug 2022)
  
• Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review (31 Jul 2022)
  
• Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy in vitro and in vivo (25 Jul 2022)